Zacks Investment Research upgraded shares of Vical (NASDAQ:VICL) from a hold rating to a buy rating in a report released on Saturday, March 17th. Zacks Investment Research currently has $1.75 price objective on the biotechnology company’s stock.
According to Zacks, “Vical researches and develops biopharmaceutical products based on its patented DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. Potential applications of the company’s DNA delivery technology include DNA vaccines for infectious diseases or cancer, in which the expressed protein is an immunogen; cancer immunotherapeutics, in which the expressed protein is an immune system stimulant; and cardiovascular therapies, in which the expressed protein is an angiogenic growth factor. The company is developing certain infectious disease vaccines and cancer therapeutics internally. In addition, the company collaborates with major pharmaceutical companies and biotechnology companies that give it access to complementary technologies or greater resources. These strategic partnerships provide the company with mutually beneficial opportunities to expand its product pipeline and address significant unmet medical needs. “
A number of other research analysts have also recently commented on VICL. ValuEngine raised Vical from a strong sell rating to a sell rating in a research report on Friday, February 2nd. HC Wainwright reiterated a buy rating and set a $5.00 price objective on shares of Vical in a research note on Thursday, February 1st. One investment analyst has rated the stock with a sell rating and four have given a buy rating to the company. The company currently has an average rating of Buy and an average target price of $5.25.
VICL stock traded up $0.01 during mid-day trading on Friday, reaching $1.46. The company’s stock had a trading volume of 340,405 shares, compared to its average volume of 136,637. The company has a market cap of $31.85, a P/E ratio of -1.45 and a beta of 1.17. Vical has a 12 month low of $1.32 and a 12 month high of $3.70.
Vical (NASDAQ:VICL) last released its quarterly earnings data on Thursday, March 15th. The biotechnology company reported ($0.21) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.11) by ($0.10). The firm had revenue of $3.95 million for the quarter, compared to the consensus estimate of $4.60 million. Vical had a negative net margin of 93.78% and a negative return on equity of 28.22%. research analysts predict that Vical will post -0.56 EPS for the current year.
In related news, major shareholder Armistice Capital Master Fund bought 100,000 shares of the company’s stock in a transaction that occurred on Monday, January 22nd. The stock was bought at an average cost of $1.43 per share, for a total transaction of $143,000.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 5.98% of the company’s stock.
Several large investors have recently made changes to their positions in VICL. Acadian Asset Management LLC bought a new position in Vical during the 4th quarter valued at approximately $140,000. Geode Capital Management LLC increased its holdings in shares of Vical by 195.0% in the 4th quarter. Geode Capital Management LLC now owns 111,688 shares of the biotechnology company’s stock worth $204,000 after purchasing an additional 73,822 shares in the last quarter. Alambic Investment Management L.P. bought a new stake in shares of Vical in the 4th quarter worth $214,000. Millennium Management LLC bought a new stake in shares of Vical in the 4th quarter worth $256,000. Finally, New York State Common Retirement Fund increased its holdings in shares of Vical by 83.6% in the 2nd quarter. New York State Common Retirement Fund now owns 130,706 shares of the biotechnology company’s stock worth $354,000 after purchasing an additional 59,504 shares in the last quarter. 46.91% of the stock is owned by hedge funds and other institutional investors.
COPYRIGHT VIOLATION NOTICE: “Vical (VICL) Stock Rating Upgraded by Zacks Investment Research” was reported by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was illegally copied and republished in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.dispatchtribunal.com/2018/04/08/zacks-investment-research-upgrades-vical-vicl-to-buy.html.
Vical Incorporated researches and develops biopharmaceutical products based on its deoxyribonucleic acid (DNA) delivery technologies for the prevention and treatment of life-threatening diseases. The Company has approximately four active, independent, or partnered development programs in the areas of infectious disease including Phase III clinical trial of ASP0113 for prevention of cytomegalovirus (CMV) reactivation in stem cell transplant recipients and Phase II clinical trial of ASP0113 for prevention of CMV infection in kidney transplant recipients; Phase I/II clinical trial of its therapeutic genital herpes vaccine, designed to reduce viral shedding and genital herpes lesions in herpes simplex virus type 2 (HSV-2) infected patients; an ongoing Phase I program of VL-2397 for invasive fungal infections, and completed preclinical program, with an allowed investigational new drug application (IND) using its CyMVectin prophylactic vaccine formulated with its Vaxfectin adjuvant.
Get a free copy of the Zacks research report on Vical (VICL)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.